QR Code

Sequential alternation of nal-IRI/5-FU and gemcitabine/nab-paclitaxel versus nal-IRI/5-FU versus gemcitabine/nab-paclitaxel in first-line metastatic pancreatic cancer: results of the randomized phase II PRODIGE 61—FUNGEMAX trial (France)Research in context

Summary: Background: New chemotherapeutic approaches are still needed to improve survival and quality of life in metastatic pancreatic ductal adenocarcinoma (mPDAC). In the absence of validated predictive biomarkers, first-line sequential treatment strategies may allow to delay chemoresistance and...

Full description

Saved in:
Main Authors: Julien Taieb, Simon Pernot, Frédéric Thuillier, Alexis Delattre, Erwan Vo-Quang, Caroline Petorin, Vincent Bourgeois, David Tougeron, Franck Audemar, Carole Vitellius, Laurent Mosser, Jérôme Desrame, Frédéric Di Fiore, Yves Rinaldi, Anna Pellat, Marion Bolliet, Fabienne Watelle, Hervé Perrier, Olivier Dubreuil, Come Lepage, Jean-Baptiste Bachet
Format: Artigo
Language:Inglês
Published: Elsevier 2026-06-01
Series:EClinicalMedicine
Subjects:
Sequential treatment
Pancreatic cancer
Nal-IRI
Nab-paclitaxel
Gemcitabine
Online Access:http://www.sciencedirect.com/science/article/pii/S2589537026002464
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items